Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP) determined that expected clinical benefits of seladelpar include delayed development of liver fibrosis and cirrhosis, potentially ...

The FDA has granted Breakthrough Therapy designation to tolebrutinib for treating adults with non-relapsing secondary ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

The U.S. Food and Drug Administration in August granted accelerated approval to seladelpar, which the Foster City, Calif., company markets as Livdelzi. The drug was the key asset in Gilead's $4.3 ...

A 45-year-old man from Shimla with advanced liver cirrhosis and dual food pipe obstructions underwent a successful endoscopic ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

Have you been boozing more often than usual?A new blood test might be able to tell if you’re damaging your liver from ...

Yepuri, MDPrimary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease ...

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosisDesignation is based on ...

New research from Karolinska Institutet in Sweden highlights the possibility of screening people with type 2 diabetes for liver damage at the same time as they undergo screening for eye disease. The ...

A new study finds that a blood test may be a more reliable indicator of liver disease than asking how much a person drinks. ...